EIF2AK2 and myotonic dystrophy type 1: The second drug, the oxindole/imidazole derivative C16, is an inhibitor of the dsRNA-dependent protein kinase PKR (PKR-I), which is activated by expanded CUG repeats in DM1 (Tian et al., 2000, 2005; Huichalaf et al., 2010; Wojciechowska et al., 2014).